Synthetic Biologics Inc Up 0.7% To $1.43 After Earnings

Thursday, August 11, 2022 - Synthetic Biologics Inc (SYN) reported downside earnings and in line revenues.

The company reported an EPS loss of $0.31 per share. The firm reported an EPS loss of $0.02 per share in the year-ago quarter. The decline in Synthetic Biologics Inc's annual growth rate represents how the business isn't performing well amid current economic conditions.

Synthetic Biologics Inc Q2 2022 revenue came in at $0.00. The company achieved 0% growth year-over-year compared to the firm's revenue of $0.00 from the year-ago quarter. The lower earnings growth relative to revenue signals Synthetic Biologics Inc has not been able to improve its profit margin.

The stock is up 0.7% to $1.43 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

Trading in the five days leading up to the report earned Synthetic Biologics Inc a Bearish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 51. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria.